跳转至内容
Merck

38956

Supelco

辛伐他汀

analytical standard

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C25H38O5
CAS号:
分子量:
418.57
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

analytical standard

品質等級

化驗

≥98.0% (HPLC)

光學活性

[α]/D +275±25°, c = 1 in acetonitrile

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

雜質

≤0.5% water

mp

127-132 °C (lit.)

應用

forensics and toxicology
pharmaceutical (small molecule)
veterinary

格式

neat

儲存溫度

2-8°C

SMILES 字串

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC

InChI

1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

InChI 密鑰

RYMZZMVNJRMUDD-HGQWONQESA-N

基因資訊

human ... HMGCR(3156)

正在寻找类似产品? 访问 产品对比指南

應用

有关合适仪器技术的更多信息,请参考产品分析证书。如需进一步支持,请联系技术服务。

生化/生理作用

辛伐他汀是HMG-CoA还原酶的特异性抑制剂,HMG-CoA还原酶是催化HMG-CoA转化为甲羟戊酸的酶,其是胆固醇生物合成的早期步骤。由于它可以降低低密度脂蛋白和甘油三酯的水平,并提高高密度脂蛋白水平,因而可用于治疗高胆固醇血症。辛伐他汀是一种内酯,其在体内 易于水解成相应的β-羟基酸,并可以在使用前用溶于EtOH中的NaOH进行活化。它是洛伐他汀的合成类似物(货M2147)。

象形圖

Health hazard

訊號詞

Warning

危險聲明

危險分類

Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A Marot et al.
Acta clinica Belgica, 66(2), 134-136 (2011-06-03)
Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy. Predisposing factors include comorbidities and the concomitant use of cytochrome P-450 (CYP) 3A4 inhibitors. We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone
L B Ramsey et al.
Clinical pharmacology and therapeutics, 96(4), 423-428 (2014-06-12)
Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association
Gerard J Criner et al.
The New England journal of medicine, 370(23), 2201-2210 (2014-05-20)
Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized
Stephen J Nicholls et al.
The American journal of cardiology, 105(1), 69-76 (2010-01-28)
Statins are the most commonly prescribed agents for lowering levels of low-density lipoprotein (LDL) cholesterol. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statins, the impact of increasing dose has not been fully elucidated. An individual
Daniel F McAuley et al.
The New England journal of medicine, 371(18), 1695-1703 (2014-10-01)
Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门